<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065880</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01505; ch19Lardinois</org_study_id>
    <nct_id>NCT04065880</nct_id>
  </id_info>
  <brief_title>Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation</brief_title>
  <official_title>Neoveil® Versus TachoSil® for the Treatment of Pulmonary Air Leaks Following Lung Operation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative prolonged air leak (PAL), referring to the passage of air from the lung&#xD;
      parenchyma into the pleural space, is one of the most frequent postoperative complications&#xD;
      after lung resection. To control air leak, there are two different products certified since&#xD;
      years: TachoSil® and Neoveil®. This study is to investigate the difference of TachoSil® and&#xD;
      Neoveil® in patients with PAL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">July 31, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Blinded participants and unblinded investigators and evaluators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time required till air leak closure has occurred (hours)</measure>
    <time_frame>end of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)</time_frame>
    <description>time interval between end of the operation (closure of the skin) and air leak closure (less than 30ml on the digitalized drainage system).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of air leak (binary outcome 0/1), i.e. air loss &gt; 30ml</measure>
    <time_frame>end of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)</time_frame>
    <description>Incidence of air leak (binary outcome 0/1), i.e. air loss &gt; 30ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of air leak (continuous outcome, ml)</measure>
    <time_frame>end of the operation (0 hours) until removal of the chest tubes or re-operation in case of prolonged air leak (first postoperative day)</time_frame>
    <description>Intensity of air leak (continuous outcome, ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of prolonged air leak (&gt;10 days) (binary outcome 0/1)</measure>
    <time_frame>assessed at 10th postoperative day</time_frame>
    <description>Incidence of prolonged air leak (&gt;10 days) (binary outcome 0/1)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Prolonged Air Leak</condition>
  <condition>Postoperative Air Leak</condition>
  <arm_group>
    <arm_group_label>TachoSil®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TachoSil® is a collagen sponge coated with the human coagulation factors fibrinogen and thrombin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoveil®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoveil® sheet made of polyglycolic acid (PGA). It is a biodegradable, thermoplastic and non-antigenic polymer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TachoSil®</intervention_name>
    <description>topical absorbable fibrin sealant patch applied directly on the lung area with air fistula.</description>
    <arm_group_label>TachoSil®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neoveil®</intervention_name>
    <description>bioabsorbable soft-tissue reinforcement material applied on the normal shape of the lung at the end of the operation.</description>
    <arm_group_label>Neoveil®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a pulmonary air leak following open lung surgery, regardless of whether&#xD;
             an anatomical or atypical resection was performed&#xD;
&#xD;
          -  Patients who are able to decide for themselves whether to participate in the study or&#xD;
             not ( for example due to language problems, mental disorders, dementia of the&#xD;
             participant)&#xD;
&#xD;
          -  Patients who are not family member or employee of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to follow the procedures of the study, for example, due to language&#xD;
             problems, mental disorders, dementia of the participant&#xD;
&#xD;
          -  Enrolment of the investigator, his/her family members, employees and other dependent&#xD;
             persons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Lardinois, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Surgery, University Hospital Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Thoracic Surgery, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung resection</keyword>
  <keyword>TachoSil®</keyword>
  <keyword>Neoveil®</keyword>
  <keyword>air leak closure</keyword>
  <keyword>drainage time</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

